Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 251 to 260 of 305

Type: GuidanceRemove Type: Guidance filter

Guidance and quality standards awaiting development
Title	Type
Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081	Technology appraisal guidance
Surgical Mesh for ventral hernias	Health technology evaluation
Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]	Technology appraisal guidance
Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment [ID6631]	Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]	Technology appraisal guidance
Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]	Technology appraisal guidance
Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]	Technology appraisal guidance
Tarlatamamb for treating small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]	Technology appraisal guidance
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]	Technology appraisal guidance
Technologies to support home monitoring of vision change in macular disease	Health technology evaluation

Results per page

10
25
50
All